Revvity (RVTY) has exhibited an impressive financial performance in the recent past. The company's Q4 earnings surpassed estimates and beat expectations by $0.05 EPS, leading to a spike of 5% in their shares, and interestingly, their yearly earnings for 2025 also show promising signals. Notable transactions featuring the stock included Slocum Gordon & Co LLP, Janney Montgomery Scott LLC, and Trust Point Inc. purchasing its shares, despite some opting to sell, including insiders Michelle Mcmurry-heath and Joel S. Goldberg. An increase in stock price target by Barclays to $140.00 attests to the firm's robust financial health, a sentiment echoed by other firms including KeyCorp and Raymond James. Notwithstanding positive earnings, RVTY stock fell on the announcement for FDA approval of their Automated Testosterone Test, hinting at possible market skepticism about the product. Revvity also announced a partnership with Element Biosciences, aimed at transforming the field of Neonatal Genetic Testing, which underlines the innovative edge of the company. However, despite delivering strong Q4 revenue growth and predicting earnings to beat guidance for 2024, RVTY predicts lower earnings for 2025.
Revvity RVTY News Analytics from Mon, 15 Apr 2024 07:00:00 GMT to Sat, 08 Feb 2025 12:17:41 GMT -
Rating 7
- Innovation 4
- Rumor -8
